NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Price & Overview

NASDAQ:NRSN • IL0011809592

Current stock price

0.76 USD
+0.01 (+1.33%)
Last:

The current stock price of NRSN is 0.76 USD. Today NRSN is up by 1.33%. In the past month the price decreased by -11.18%. In the past year, price decreased by -23.74%.

NRSN Key Statistics

52-Week Range0.63 - 2.6
Current NRSN stock price positioned within its 52-week range.
1-Month Range0.63 - 1.05
Current NRSN stock price positioned within its 1-month range.
Market Cap
25.384M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.54
Dividend Yield
N/A

NRSN Stock Performance

Today
+1.33%
1 Week
+3.42%
1 Month
-11.18%
3 Months
-3.19%
Longer-term
6 Months -39.60%
1 Year -23.74%
2 Years -58.52%
3 Years -56.10%
5 Years N/A
10 Years N/A

NRSN Stock Chart

NEUROSENSE THERAPEUTICS LTD / NRSN Daily stock chart

NRSN Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NRSN. When comparing the yearly performance of all stocks, NRSN is a bad performer in the overall market: 81.86% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NRSN Earnings

Next Earnings DateN/A
Last Earnings DateMar 25, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

NRSN Forecast & Estimates

9 analysts have analysed NRSN and the average price target is 8.54 USD. This implies a price increase of 1024.01% is expected in the next year compared to the current price of 0.76.


Analysts
Analysts82.22
Price Target8.54 (1023.68%)
EPS Next Y27.28%
Revenue Next YearN/A

NRSN Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

NRSN Financial Highlights

Over the last trailing twelve months NRSN reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 25.92% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-10.21M
Industry RankSector Rank
PM (TTM) N/A
ROA -1037.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-292.8%
Sales Q2Q%N/A
EPS 1Y (TTM)25.92%
Revenue 1Y (TTM)N/A

NRSN Ownership

Ownership
Inst Owners0.99%
Shares33.40M
Float27.00M
Ins Owners12.26%
Short Float %1.82%
Short Ratio2.39

About NRSN

Company Profile

NRSN logo image Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Company Info

IPO: 2021-12-09

NEUROSENSE THERAPEUTICS LTD

11 Hamenofim St., Building B

Herzliya IL

Employees: 15

NRSN Company Website

NRSN Investor Relations

Phone: 97297996183

NEUROSENSE THERAPEUTICS LTD / NRSN FAQ

Can you describe the business of NEUROSENSE THERAPEUTICS LTD?

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease


What is the current price of NRSN stock?

The current stock price of NRSN is 0.76 USD. The price increased by 1.33% in the last trading session.


What is the dividend status of NEUROSENSE THERAPEUTICS LTD?

NRSN does not pay a dividend.


What is the ChartMill rating of NEUROSENSE THERAPEUTICS LTD stock?

NRSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the Price/Earnings (PE) ratio of NEUROSENSE THERAPEUTICS LTD (NRSN)?

NEUROSENSE THERAPEUTICS LTD (NRSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.54).


What is the Short Interest ratio of NEUROSENSE THERAPEUTICS LTD (NRSN) stock?

The outstanding short interest for NEUROSENSE THERAPEUTICS LTD (NRSN) is 1.82% of its float.